Assay and Drug Development Technologies - 24

RYAN ET AL.
differentiate as they would in vivo without restrictions imposed
by artificial matrices. As its principle component is standard
culturemedium, our CSM can be formulated tomeet the specific
nutritional requirements of individual cell lines. We have cultured
a range of cell lines using our technology, including
tumor-forming and nontumor-forming stem and primary cells,
andwe are currently testing a number ofprotocols to coculture a
wide range of cell types in addition to the development of
normal 3D models to examine the effects of new therapeutic
approaches.
Our CSM is simple to use, requiring little technical expertise,
and 3D cultures can be transferred between culture vessels, fed,
and sampled with ease. When the desired stage of 3D model
formation has been achieved, the culture can be treated with an
inactivation solution. This solution dissociates the CSM and
allows sedimentation of the 3D structures, permitting their
recovery from the medium and allowing, for example, media
exchange, fixation, drug addition, and imaging, without impacting
on their geometryorcomposition.Data suggests that our
system is capable of generating and maintaining large volumes
of 3D culture models in a variety of cell culture vessels. Characterization
of these structures is ongoing.101-103,* These traits
combined with its capacity for use in miniaturization experiments
make this technology compatible with bothHTS and HCS
platforms, for which it has been specifically engineered.
DISCUSSION
There are many options available with regard to 3D cell culture
systems. The method chosen will depend upon the desired
experimental output. Unfortunately, in many cases, the input
vastly exceeds the output. A 3D cell culture technology that can
accommodate both the quantitative aspect of HTS and the
qualitative aspect ofHCS could hold major potential in relation
to drug screening, target identification, and validation, in addition
to elucidating mechanisms ofdrug resistance. The ability
to facilitate thiswhile remaining economicallyviablewouldbe a
significant advancement in the field ofdrug discovery and have
many positive implications for the bench-to-bedside approach.
We are hopeful that our CSMwill provide means to dojust that.
ACKNOWLEDGMENTS
S.-L.R. is supported by a Supervisor Scholarship from QUT.
K.O.B. is supported by a Senior Clinical Research Fellow
(SCRF) award Queensland Government, Office of Health and
Medical Research.
*Baird AM: Targeting NF-kB pathways as a means to overcome cisplatin resistance
in non-small cell lung cancer. Abstract presented at the Australian Lung Cancer
Conference, Brisbane, Australia, 2014.
DISCLOSURE STATEMENT
Dr. Anthony Davies is the inventor of the Colloidal Suspension
Media (CSM) and is also a major shareholder and a
director of the company that currently commercializes this
technology. For all other authors, no competing financial interests
exist.
REFERENCES
1. Harrison RG: Observations of the living developing nerve fiber. Anat Rec 1907;
1:116-128.
2. Box C, Rogers SJ, Mendiola M, Eccles SA: Tumour-microenvironmental
interactions: paths to progression and targets for treatment. Semin Cancer
Biol 2010;20:128-138.
3. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and
therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
4. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev
Cancer 2009;9:239-252.
5. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell 2010;141:52-67.
6. Meads MB, Gatenby RA, Dalton WS: Environment-mediated drug resistance:
a major contributor tominimal residual disease. NatRevCancer2009;9:665-674.
7. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis
revisited. Nat Rev Cancer 2003;3:453-458.
8. Sorokin L: The impact of the extracellular matrix on inflammation. Nat Rev
Immunol 2010;10:712-723.
9. Bissell MJ, Rizki A, Mian IS: Tissue architecture: the ultimate regulator of
breast epithelial function. Curr Opin Cell Biol 2003;15:753-762.
10. Cukierman E, Pankov R, Stevens DR, Yamada KM: Taking cell-matrix adhesions
to the third dimension. Science 2001;294:1708-1712.
11. Cukierman E, Pankov R, Yamada KM: Cell interactions with three-dimensional
matrices. Curr Opin Cell Biol 2002;14:633-639.
12. Nelson CM, Bissell MJ: Of extracellular matrix, scaffolds, and signaling: tissue
architecture regulates development, homeostasis, and cancer. Annu Rev Cell
Dev Biol 2006;22:287-309.
13. Edmondson R, Broglie JJ, Adcock AF, Yang L: Three-dimensional cell culture
systems and their applications in drug discovery and cell-based biosensors.
Assay Drug Dev Technol 2014;12:207-218.
14. Bissell MJ, Kenny PA, Radisky DC: Microenvironmental regulators of tissue
structure and function also regulate tumor induction and progression: the
role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp
Quant Biol 2005;70:343-356.
15. Kenny PA: Three-dimensional extracellular matrix culture models of EGFR
signalling and drug response. Biochem Soc Trans 2007;35:665-668.
16. Lee GY, Kenny PA, Lee EH, Bissell MJ: Three-dimensional culture models of normal
and malignant breast epithelial cells. NatMethods 2007;4:359-365.
17. Weaver VM, et al.: Reversion of the malignant phenotype of human breast
cells in three-dimensional culture and in vivo by integrin blocking antibodies.
J Cell Biol 1997;137:231-245.
18. Bhadriraju K, Chen CS: Engineering cellular microenvironments to improve
cell-based drug testing. Drug Discov Today 2002;7:612-620.
19. Kunz-Schughart LA, Kreutz M, Knuechel R: Multicellular spheroids: a threedimensional
in vitro culture system to study tumour biology. Int J Exp Pathol
1998;79:1-23.
20. Mueller-Klieser W: Multicellular spheroids. A review on cellular aggregates in
cancer research. J Cancer Res Clin Oncol 1987;113:101-122.
21. Sutherland RM: Cell and environment interactions in tumor microregions: the
multicell spheroid model. Science 1988;240:177-184.
22. Johnson J, Decker S, Zaharevitz D, et al.: Relationships between drug activity
in NCI preclinical in vitro and in vivo models and early clinical trials. Br J
Cancer 2001;84:1424-1431.
24 ASSAY and Drug Development Technologies
ª 2022 MARY ANN LIEBERT, INC.
Assay and Drug Development Technologies

Table of Contents for the Digital Edition of Assay and Drug Development Technologies
